合成乙酰水杨酸铼化合物对人星形细胞瘤细胞系的影响。

Journal of Cancer Science & Therapy Pub Date : 2018-01-01 Epub Date: 2018-02-26 DOI:10.4172/1948-5956.1000512
Hirendra N Banerjee, Deidre Vaughan, Ava Boston, Gabriel Thorne, Gloria Payne, Josiah Sampson, Vinod Manglik, Pola Olczak, Brent V Powell, Angela Winstead, Roosevelt Shaw, Santosh K Mandal
{"title":"合成乙酰水杨酸铼化合物对人星形细胞瘤细胞系的影响。","authors":"Hirendra N Banerjee,&nbsp;Deidre Vaughan,&nbsp;Ava Boston,&nbsp;Gabriel Thorne,&nbsp;Gloria Payne,&nbsp;Josiah Sampson,&nbsp;Vinod Manglik,&nbsp;Pola Olczak,&nbsp;Brent V Powell,&nbsp;Angela Winstead,&nbsp;Roosevelt Shaw,&nbsp;Santosh K Mandal","doi":"10.4172/1948-5956.1000512","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Because of the scarcity of suitable brain cancer drugs, researchers are frantically trying to discover novel and highly potent drugs free of side effects and drug-resistance. Rhenium compounds are known to be nontoxic and exhibit no drug resistance. For that reason, we have developed a series of novel rhenium acetylsalicylato (RAC or ASP) complexes to test their cytotoxicity on brain cancer cells. Also we have attempted to explore the DNAbinding properties of these compounds because many drugs either directly or indirectly bind to DNA.</p><p><strong>Methods: </strong>We have treated the RAC series compounds on human astrocytoma brain cancer cell lines and rat normal brain astrocyte cells and determined the efficacy of these complexes through in vitro cytotoxicity assay. We carried out the DNA-binding study through UV titrations of a RAC compound with DNA. Also we attempted to determine the planarity of the polypyridyl ligands of the RAC series compounds using DFT calculations.</p><p><strong>Results: </strong>RAC6 is more potent than any other RAC series compounds on HTB-12 human astrocytoma cancer cells as well as on Glioblastoma Multiforme D54 cell lines. In fact, The IC-50 value of RAC6 on HTB-12 cancer cells is approximately 2 μM. As expected, the RAC series compounds were not active on normal cells. The DFT calculations on the RAC series compounds were done and suggest that the polypyridyl ligands in the complexes are planar. The UV-titrations of RAC9 with DNA were carried out. It suggests that RAC9 and possibly all RAC series compounds bind to minor grooves of the DNA.</p><p><strong>Conclusion: </strong>Because of the very low activity of RAC6 on normal cells and low lC<sub>50</sub> value of on astrocytoma (HTB-12) cell lines, it is possible that RAC6 and its derivatives may potentially find application in the treatment of brain cancers. The DFT calculations and UV titrations suggest that RAC series compounds either bind to DNA intercalatively or minor grooves of the DNA or both. However, it is highly premature to make any definite statement in the absence of other techniques.</p>","PeriodicalId":15170,"journal":{"name":"Journal of Cancer Science & Therapy","volume":"10 2","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4172/1948-5956.1000512","citationCount":"4","resultStr":"{\"title\":\"The Effects of Synthesized Rhenium Acetylsalicylate Compounds on Human Astrocytoma Cell Lines.\",\"authors\":\"Hirendra N Banerjee,&nbsp;Deidre Vaughan,&nbsp;Ava Boston,&nbsp;Gabriel Thorne,&nbsp;Gloria Payne,&nbsp;Josiah Sampson,&nbsp;Vinod Manglik,&nbsp;Pola Olczak,&nbsp;Brent V Powell,&nbsp;Angela Winstead,&nbsp;Roosevelt Shaw,&nbsp;Santosh K Mandal\",\"doi\":\"10.4172/1948-5956.1000512\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Because of the scarcity of suitable brain cancer drugs, researchers are frantically trying to discover novel and highly potent drugs free of side effects and drug-resistance. Rhenium compounds are known to be nontoxic and exhibit no drug resistance. For that reason, we have developed a series of novel rhenium acetylsalicylato (RAC or ASP) complexes to test their cytotoxicity on brain cancer cells. Also we have attempted to explore the DNAbinding properties of these compounds because many drugs either directly or indirectly bind to DNA.</p><p><strong>Methods: </strong>We have treated the RAC series compounds on human astrocytoma brain cancer cell lines and rat normal brain astrocyte cells and determined the efficacy of these complexes through in vitro cytotoxicity assay. We carried out the DNA-binding study through UV titrations of a RAC compound with DNA. Also we attempted to determine the planarity of the polypyridyl ligands of the RAC series compounds using DFT calculations.</p><p><strong>Results: </strong>RAC6 is more potent than any other RAC series compounds on HTB-12 human astrocytoma cancer cells as well as on Glioblastoma Multiforme D54 cell lines. In fact, The IC-50 value of RAC6 on HTB-12 cancer cells is approximately 2 μM. As expected, the RAC series compounds were not active on normal cells. The DFT calculations on the RAC series compounds were done and suggest that the polypyridyl ligands in the complexes are planar. The UV-titrations of RAC9 with DNA were carried out. It suggests that RAC9 and possibly all RAC series compounds bind to minor grooves of the DNA.</p><p><strong>Conclusion: </strong>Because of the very low activity of RAC6 on normal cells and low lC<sub>50</sub> value of on astrocytoma (HTB-12) cell lines, it is possible that RAC6 and its derivatives may potentially find application in the treatment of brain cancers. The DFT calculations and UV titrations suggest that RAC series compounds either bind to DNA intercalatively or minor grooves of the DNA or both. However, it is highly premature to make any definite statement in the absence of other techniques.</p>\",\"PeriodicalId\":15170,\"journal\":{\"name\":\"Journal of Cancer Science & Therapy\",\"volume\":\"10 2\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.4172/1948-5956.1000512\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Cancer Science & Therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4172/1948-5956.1000512\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2018/2/26 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cancer Science & Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/1948-5956.1000512","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/2/26 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 4

摘要

目的:由于合适的脑癌药物的稀缺,研究人员正疯狂地试图发现新的和高效的药物,无副作用和耐药。铼化合物是无毒的,没有抗药性。因此,我们开发了一系列新的乙酰水杨酸铼(RAC或ASP)复合物来测试它们对脑癌细胞的细胞毒性。此外,由于许多药物直接或间接与DNA结合,我们也试图探索这些化合物的DNA结合特性。方法:将RAC系列化合物分别作用于人星形细胞瘤脑癌细胞株和大鼠正常脑星形细胞,并通过体外细胞毒实验测定其作用效果。我们通过紫外滴定RAC化合物与DNA进行了DNA结合研究。我们还尝试用DFT计算来确定RAC系列化合物的多吡啶配体的平面度。结果:RAC6对HTB-12人星形细胞瘤癌细胞和多形性胶质母细胞瘤D54细胞系的作用强于其他任何RAC系列化合物。事实上,RAC6对HTB-12癌细胞的IC-50值约为2 μM。正如预期的那样,RAC系列化合物对正常细胞没有活性。对RAC系列化合物进行了DFT计算,结果表明配合物中的多吡啶基配体是平面的。用DNA对RAC9进行紫外滴定。这表明RAC9和可能所有RAC系列化合物与DNA的小凹槽结合。结论:由于RAC6对正常细胞的活性很低,对星形细胞瘤(HTB-12)细胞株的lC50值很低,RAC6及其衍生物可能在脑癌的治疗中有潜在的应用前景。DFT计算和紫外滴定表明,RAC系列化合物要么与DNA插入性结合,要么与DNA的小凹槽结合,要么两者兼而有之。然而,在缺乏其他技术的情况下,做出任何明确的声明都是非常不成熟的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

The Effects of Synthesized Rhenium Acetylsalicylate Compounds on Human Astrocytoma Cell Lines.

The Effects of Synthesized Rhenium Acetylsalicylate Compounds on Human Astrocytoma Cell Lines.

The Effects of Synthesized Rhenium Acetylsalicylate Compounds on Human Astrocytoma Cell Lines.

The Effects of Synthesized Rhenium Acetylsalicylate Compounds on Human Astrocytoma Cell Lines.

Purpose: Because of the scarcity of suitable brain cancer drugs, researchers are frantically trying to discover novel and highly potent drugs free of side effects and drug-resistance. Rhenium compounds are known to be nontoxic and exhibit no drug resistance. For that reason, we have developed a series of novel rhenium acetylsalicylato (RAC or ASP) complexes to test their cytotoxicity on brain cancer cells. Also we have attempted to explore the DNAbinding properties of these compounds because many drugs either directly or indirectly bind to DNA.

Methods: We have treated the RAC series compounds on human astrocytoma brain cancer cell lines and rat normal brain astrocyte cells and determined the efficacy of these complexes through in vitro cytotoxicity assay. We carried out the DNA-binding study through UV titrations of a RAC compound with DNA. Also we attempted to determine the planarity of the polypyridyl ligands of the RAC series compounds using DFT calculations.

Results: RAC6 is more potent than any other RAC series compounds on HTB-12 human astrocytoma cancer cells as well as on Glioblastoma Multiforme D54 cell lines. In fact, The IC-50 value of RAC6 on HTB-12 cancer cells is approximately 2 μM. As expected, the RAC series compounds were not active on normal cells. The DFT calculations on the RAC series compounds were done and suggest that the polypyridyl ligands in the complexes are planar. The UV-titrations of RAC9 with DNA were carried out. It suggests that RAC9 and possibly all RAC series compounds bind to minor grooves of the DNA.

Conclusion: Because of the very low activity of RAC6 on normal cells and low lC50 value of on astrocytoma (HTB-12) cell lines, it is possible that RAC6 and its derivatives may potentially find application in the treatment of brain cancers. The DFT calculations and UV titrations suggest that RAC series compounds either bind to DNA intercalatively or minor grooves of the DNA or both. However, it is highly premature to make any definite statement in the absence of other techniques.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信